Bapten, a medication that has shown promise in the treatment of bowed tendons, has been taken off the market because of reports of a troubling side effect. A prepared statement from Boehringer Ingelheim, the pharmaceutical company that distributes the drug, described the suspension of sales as "temporary."
According to the statement, the
To continue reading this article, become a member of TheHorse.com.
It's FREE and you'll get full access to more than 20,000 articles, video, free reports & more.
